Validity of a Brief Computerized Cognitive Screening Test in Dementia

Abstract

Background: While preliminary evidence supports the criterion validity of the CogState computerized brief battery in mild cognitive impairment (MCI) and Alzheimer disease (AD), definitive validation studies examining a wider range of dementia-related disorders relative to conventional neuropsychological techniques are necessary. Methods: Participants satisfying clinical consensus criteria for dementia (AD, n = 37; frontotemporal dementia, n = 7; and dementia with Lewy bodies, n = 5), MCI (n = 16), and the healthy controls (n = 22) were administered a battery of brief neuropsychological and select computerized (CogState) cognitive tests. The battery, administered through the University of Michigan Alzheimer’s Disease Research Center, included measures of processing speed, attention, working memory, and learning. Results: CogState and standard neuropsychological task scores were significantly lower for dementia participants than that of the nondementia groups (P < .05), with a single CogState test distinguishing control from MCI participants, but minimal differentiation existing between dementias using the CogState. Correlations were modest between conventional and computerized test scores, covering matching domains and mostly reflecting the multidimensional nature of cognitive paradigms. Conclusions: Results support the clinical validity of this brief computerized screening battery when used in established dementias, but not to differentiate between various dementias, and suggest that the select CogState battery’s effectiveness in identifying MCI from controls was not as strong as identifying specific dementias.

Keywords

neuropsychological testing cognitive decline dementia

Get full access to this article

View all access options for this article.

References

Darby

Walsh

. Walsh's Neuropsychology: A Clinical Approach. 5th ed. Edinburgh: Elsevier; 2005.

Lezak

Howieson

Loring

. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.

Maruff

Thomas

Cysique

Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–178.

Ellis

Bush

Darby

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr. 2009;21(4):672–687.

Lim

Ellis

Harrington

Use of the CogState brief battery in the assessment of Alheimer’s disease related to cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol. 2012;34(4):345–358.

Cohen

. Statistical Power for the Behavioral Sciences. New York, NY: Lawrence Erlbaum; 1988.

Zakzanis

. Statistics to tell the truth, the whole truth and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effects size analysis for neuropsychological researchers. Arch Clin Neuropsychol. 2001;16(7):653–667.

Morris

Weintraub

Chui

The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210–216.

Petersen

. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194.

10.

McKhann

Drachman

Folstein

Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer’s disease. Neurology. 1984;34(7):939–944.

11.

Neary

Snowden

Gustafson

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–1554.

12.

McKeith

Dickson

Lowe

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872.

13.

Collie

Maruff

Snyder

Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Hum Psychopharmacol. 2006; 21(7):481–488.

14.

Maruff

Werth

Giordani

A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. Psychopharmacology (Berl). 2006;186(1):7–17.

15.

Weaver Cargin

Maruff

Collie

Masters

. Mild memory impairment in healthy older adults is distinct from normal aging. Brain Cogn. 2006;60(2):146–155.

16.

Folstein

McHugh

. Mini-mental State. J Psychiatr Res. 1975;12(3):189–198.

17.

Arthur

Jagger

Lindesay

Using an annual over-75 health check to screen for depression: validation of the short Geriatric Depression Scale (GDS15) within general practice. Int J Geriatr Psychiat. 1999;14(6):431–439.

18.

Armitage

. An analysis of certain psychological tests used in the evaluation of brain injury. Psychol Monogr. 1946;60:1–48.

19.

Wechsler

. WAIS-R Manual. New York, NY: Psychological Corporation; 1981.

20.

Benton

Sivan

Hamsher K d

Contributions to Neuropsychological Assessment: A Clinical Manual. 2nd ed. New York, NY: Oxford University Press; 1994.

21.

Wechsler

. WAIS-III/WMS-III Technical Manual. San Antonio: The Psychological Corporation; 1997.

22.

Wechsler

. Wechsler Memory Scale-Revised Manual. San Antonio: The Psychological Corporation; 1987.

23.

Heaton

. Wisconsin Card Sorting Test (WCST). Odessa, FL: Psychological Assessment Resources; 1981.

24.

Spreen

Strauss

. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. Oxford: Oxford University Press; 1998.

25.

Falleti

Maruff

Collie

Darby

. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol. 2006;28(7):1095–1112.

26.

Cumming

Maillardet

. Confidence intervals and replication: where will the next mean fall? Psychol Methods. 2006;11(3):217–227.

27.

McKeith

Del Ser

Spano

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–2036.

28.

Walker

Ayre

Cummings

Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology. 2000;54(8):1616–1625.

29.

Collie

Makdissi

Maruff

Cognition in the days following concussion: comparison of symptomatic versus asymptomatic athletes. J Neurol Neurosurg Psychiatry. 2006;77(2):241–245.

30.

Darby

Pietrzak

Fredrickson

Intra-individual cognitive decline using a brief computerized cognitive screening test. Alzheimers Demen. 2012;8(2):95–104.

31.

Darby

Maruff

Collie

McStephen

. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59(7):1042–1046.

32.

Fredrickson

Maruff

Woodward

Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology. 2010;34(2):65–75.

33.

Maruff

Collie

Darby

Subtle memory decline over 12 months in mild cognitive impairment. Dement Geriatr Cogn Disord. 2004;18(3):342–348.

34.

Hammers

Spurgeon

Ryan

Reliability of repeated cognitive assessmetn of dementia using a brief computerized battery. Am J Alzheimers Dis Other Demen. 2011;26(4): 326–333.

35.

Chow

Hynan

Lipton

. MMSE scores decline at a greater rate in frontotemporal degeneration than in AD. Dement Geriatr Cogn Disord. 2006;22(3):194–199.

36.

Bradshaw

Saling

Hopwood

Anderson

Brodtmann

. Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease is qualitatively distinct. J Neurol Neurosurg Psychiatry. 2004;75(3):382–387.

37.

Pietrzak

Cohen

Snyder

. Spatial learning efficiency and error monitoring in normal aging: an investigation using a novel hidden maze learning test. Arch Clin Neuropsychol. 2007;22(2):235–245.